The efficancy of a new long-acting insulin degludec in patient with diabetes

The efficancy of a new long-acting insulin degludec in patient with diabetes - The efficancy of a new long-acting insulin degludec in patient with diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011567

Enrollment

100

Registered

2013-08-31

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

insulin degludec Continuing with the treatment so far

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c :more than 8.0%

Exclusion criteria

Exclusion criteria: Contraindicated patient in the attached document of insulin degludec Contraindicated patient in the attached document of diabetes drugs Hypoglycemic risk Serious heart trouble Severe hepatic dysfunction Severe renal dysfunction Internal secretion disease Needs the steroid dosage Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
Change in HbA1c and the score of Diabetes Treatment Satisfaction Questionnaire and dietary behavior Questionnaire , ITNA-1 and adverse events including hypoglycemia at 24 weeks later from an examination start	—

Secondary

Measure	Time frame
From an examination start, it is the following items 48 weeks later for up to 24 weeks. -Achievement rate of HbA1c <7.0% and <8.0% -Change in fasting blood glucose -Glycemic variability by CGM and SMBG -Change in insulin dose(daily basal insulin doses, daily total insulin doses)	—

Countries

Japan

Contacts

Public ContactMotoya Koie

Osaka Saiseikai Noe Hospital Department of Diabetes and Endocrinology

motoya.koie@noe.saiseikai.or.jp06-6932-0401

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026